➤ Get the DrugPatentWatch Daily Briefing

Get Daily Updates on Generic Entry, Litigation, Biosimilars, and more …

Serving leading biopharmaceutical companies globally:

McKinsey
Harvard Business School
Boehringer Ingelheim
McKesson
Mallinckrodt
Merck

Last Updated: October 31, 2020

DrugPatentWatch Database Preview

Claims for Patent: 9,506,058

➤ Get the DrugPatentWatch Daily Briefing
» See Plans and Pricing

« Back to Dashboard

Summary for Patent: 9,506,058
Title:Compositions for treating muscular dystrophy
Abstract: Improved compositions and methods for treating muscular dystrophy by administering antisense molecules capable of binding to a selected target site in the human dystrophin gene to induce exon skipping are described.
Inventor(s): Kaye; Edward M. (Cambridge, MA)
Assignee: Sarepta Therapeutics, Inc. (Cambridge, MA)
Application Number:14/214,567
Patent Claims: 1. An oral methylphenidate HCl solution comprising: about 0.1 mg/ml to about 10.0 mg/ml methylphenidate HCl; and about 0.5 mg/ml to about 5.0 mg/ml of at least one organic acid, the methylphenidate HCl and the at least one organic acid being dissolved in a solvent system, the solvent system comprising: about 10% to about 45% water; about 30% to about 70% of at least one polyol solvent; about 10% to about 70% of at least one glycol solvent; and wherein the oral methylphenidate HCl solution is storage stable.

2. The methylphenidate HCl solution according to claim 1, wherein the at least one organic acid is selected from the group consisting of acetic acid, ascorbic acid, citric acid, fumaric acid, malic acid, succinic acid, tartaric acid and mixtures thereof.

3. The methylphenidate HCL solution according to claim 1, wherein the at least one polyol solvent is selected from the group consisting of glycerin, sorbitol, sucrose, fructose and mixtures thereof.

4. The methylphenidate HCl solution according to claim 1, wherein the at least one glycol solvent is selected from the group consisting of propylene glycol, polyalkylene glycol products and mixtures thereof.

5. The methylphenidate HCl solution according to claim 1, further including at least one pharmaceutical additive selected from the group consisting of flavorings, colorants, buffers, preservatives and mixtures thereof.

6. An oral methylphenidate HCl solution comprising: about 0.1 mg/ml to about 10.0 mg/ml methylphenidate HCl; and about 0.5 mg/ml to about 3.0 mg/ml of at least one organic acid, the methylphenidate HCl and the at least one organic acid being dissolved in a solvent system, the solvent system comprising: about 10% to about 45% water; about 40% to about 60% of at least one polyol solvent; about 10% to about 30% of at least one glycol solvent; and wherein the oral methylphenidate HCl solution is storage stable.

7. The methylphenidate HCl solution according to claim 6, wherein at least one organic acid is selected from the group consisting of acetic acid, ascorbic acid, citric acid, fumaric acid, malic acid, succine acid, tartaric acid and mixtures thereof.

8. The methylphenidate HCl solution according to claim 6, wherein the at least one polyol solvent is selected from the group consisting of glycerin, sorbitol, sucrose, fructose and mixtures thereof.

9. The methylphenidate HCl solution according to claim 6, wherein the at least one glycol solvent is selected from the group consisting of propylene glycol, polyalkylene glycol products and mixtures thereof.

10. The methylphenidate HCl solution according to claim 6, further including at least one pharmaceutical additive selected from the group consisting of flavorings, colorants, buffers, preservatives and mixtures thereof.

11. An oral methylphenidate HCl solution comprising: about 0.1 mg/ml to about 10.0 mg/ml methylphenidate HCl; and about 0.5 mg/ml to about 1.5 mg/ml of at least one organic acid, the methylphenidate HCl and the at least one organic acid being dissolved in a solvent system, the solvent system comprising: about 30% to about 40% water; about 45% to about 55% of at least one polyol solvent; about 10% to about 20% of at least one glycol solvent; and wherein the oral methylphenidate HCl solution is storage stable.

12. The methylphenidate HCl solution according to claim 11, wherein the at least one organic acid includes citric acid.

13. The methylphenidate HCl solution according to claim 11, wherein the at least one polyol solvent includes glycerin.

14. The methylphenidate HCl solution according to claim 11, wherein the at least one glycol solvent includes polyethylene glycol.

15. The methylphenidate HCl solution according to claim 11, further including at least one pharmaceutical additive selected from the group consisting of flavorings, colorants, buffer, preservatives and mixtures thereof.

Make Better Decisions: Try a trial or see plans & pricing

Serving leading biopharmaceutical companies globally:

Johnson and Johnson
AstraZeneca
Harvard Business School
Express Scripts
McKinsey
Mallinckrodt

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.